Yuanpin Biotech possesses a mature and well-established stem cell industrialization platform, along with strong financial strength. The company has accumulated years of practical experience in biological resource storage, cell product research and development, manufacturing, and application. Additionally, it has a technical team composed mainly of stem cell industrialization talents and senior biomedical talents, laying a foundation for it to become an expert in China’s stem cell and regenerative medicine industry.

As a research and development-driven stem cell company, Yuanpin Biotech has domestic leading advantages in talent, technology, and platforms in the field of scientific research. Since its establishment, the company has been oriented toward the treatment of serious and intractable diseases. At present, the company has rapidly launched three national Class I innovative stem cell drug projects and seven clinical stem cell technology projects by leveraging its five international invention patents, 26 national invention patents, and 20 core proprietary technologies. The company has established comprehensive partnerships with institutions such as Tongji University and hospitals affiliated with the University of South China, setting up multiple research platforms to accelerate clinical research and translational application of stem cell technologies. The clinical research project “Stem Cell Therapy for Diabetic Foot”, jointly applied with the Affiliated Hospital of Guangdong Medical University, has been filed with and approved by the National Health Commission.